GAA
CRSP icon

Green Alpha Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Green Alpha Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04M Sell
55,804
-1,218
-2% -$64.2K 2.04% 11
2026
Q1 		$2.71M Buy
57,022
+1,285
+2% +$67.8K 2.67% 9
2025
Q4 		$2.92M Buy
55,737
+725
+1% +$43.4K 2.68% 7
2025
Q3 		$3.57M Sell
55,012
-3,451
-6% -$198K 3.44% 6
2025
Q2 		$2.84M Buy
58,463
+1,102
+2% +$42.6K 2.72% 9
2025
Q1 		$1.95M Buy
57,361
+32,732
+133% +$1.39M 2.08% 10
2024
Q4 		$969K Buy
24,629
+5,471
+29% +$258K 0.78% 46
2024
Q3 		$900K Sell
19,158
-479
-2% -$24.3K 0.71% 50
2024
Q2 		$1.06M Sell
19,637
-7,319
-27% -$423K 0.85% 40
2024
Q1 		$1.84M Buy
26,956
+2,406
+10% +$172K 1.33% 21
2023
Q4 		$1.54M Sell
24,550
-10,330
-30% -$571K 1.11% 23
2023
Q3 		$1.58M Buy
34,880
+507
+1% +$26.2K 1.22% 21
2023
Q2 		$1.93M Buy
34,373
+1,790
+5% +$102K 1.27% 17
2023
Q1 		$1.47M Buy
32,583
+1,937
+6% +$94.1K 1.03% 31
2022
Q4 		$1.25M Buy
30,646
+3,180
+12% +$169K 1.04% 29
2022
Q3 		$1.79M Sell
27,466
-200,820
-88% -$14.6M 1.52% 7
2022
Q2 		$13.9M Buy
228,286
+202,753
+794% +$11.9M 3.19% 6
2022
Q1 		$1.6M Buy
25,533
+8,374
+49% +$526K 1.08% 30
2021
Q4 		$1.3M Buy
17,159
+2,237
+15% +$195K 0.88% 47
2021
Q3 		$1.67M Buy
14,922
+2,214
+17% +$278K 1.15% 24
2021
Q2 		$2.06M Buy
12,708
+5,914
+87% +$719K 1.4% 7
2021
Q1 		$828K Buy
6,794
+442
+7% +$66.7K 0.82% 51
2020
Q4 		$973K Buy
+6,352
New +$751K 1.18% 27

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Green Alpha Advisors's CRSP Position: Q2 2026 in Review

Green Alpha Advisors reduced its CRISPR Therapeutics (CRSP) stake by 2.1% in Q2 2026, selling an estimated $64.2K and leaving 55,804 shares worth $3.04M. The position accounts for 2.04% of the portfolio, ranked #11.

Green Alpha Advisors first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $13.9M in Q2 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Green Alpha Advisors held 55,804 shares of CRISPR Therapeutics worth $3.04M as of Q2 2026.
  • Green Alpha Advisors sold 1,218 CRISPR Therapeutics shares in Q2 2026, an estimated $64.2K.
  • CRISPR Therapeutics made up 2.04% of Green Alpha Advisors's portfolio in Q2 2026, its #11 holding.
  • Green Alpha Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Green Alpha Advisors's CRISPR Therapeutics position peaked at $13.9M in Q2 2022.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.